Purification and identification of novel α ‐glucosidase inhibitors in okara fermented with Bacillus amyloliquefaciens YP2
Journal of the Science of Food and Agriculture · 15.01.2026 · 106 (1) · 354-364
DOI: 10.1002/jsfa.70185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, online erschienen am 10.10.2025. Verfasst von Nairu Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Green Manufacturing and Biosynthesis of Food Bioactive Substances, China General Chamber of Commerce, School of Food and Health, Be…. Hauptthemen laut MEDLINE: Bacillus amyloliquefaciens, Glycoside Hydrolase Inhibitors, Fermented Foods. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Scientific Foundation of China, Post-graduate Research Ability Improvement Program of Beijing Technology and Business University.
Abstract (Originalsprache)
Background α ‐Glucosidase inhibitors are established medications for managing type 2 diabetes. In this study, novel inhibitors were identified from okara fermented by Bacillus amyloliquefaciens , and their peptide– α ‐glucosidase interaction mechanism was investigated.
Results
The inhibition rate of α ‐glucosidase reached 84% ± 2% after eight dilutions when Bacillus amyloliquefaciens YP2 was used for okara fermentation. Metabolite analysis revealed abundant compounds in the fermented okara. Subsequently, 1‐deoxynojirimycin (DNJ) and two additional components were purified using a combination of five types of column chromatography, with DNJ demonstrating a purity of over 95%. A total of 283 peptides were identified, of which seven were predicted as candidates using bioinformatic software and in vitro assays. The half maximal inhibitory concentration (IC 50 ) value of DNJ was 1.62 mM and that of the peptide CKLLL was 6.05 mM. Molecular docking studies indicated strong affinities of both DNJ and CKLLL for α ‐glucosidase, with CKLLL binding a greater number of amino acid residues.
Conclusion
This study is the first to identify diverse α ‐glucosidase inhibitors in fermented okara. Bacillus amyloliquefaciens YP2 is a promising strain for producing α ‐glucosidase inhibitors and developing hypoglycemic food as a nutritional supplement from okara. © 2025 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Green Manufacturing and Biosynthesis of Food Bioactive Substances, China General Chamber of Commerce, School of Food and Health, Beijing Technology and Business University, Beijing, China.
- School of Food and Health, Beijing Technology and Business University, Beijing, China.
- Beijing Engineering and Technology Research Center of Food Additives, Beijing Technology & Business University, Beijing, China.
ORCID-Profile: Yunping Zhu
Förderung
- National Natural Scientific Foundation of China
- Post-graduate Research Ability Improvement Program of Beijing Technology and Business University
Zitieren
APA
Ji, N., Li, H. L., Ren, F., Zhang, Y., Zhao, B., Chen, C., & Zhu, Y. (2026). Purification and identification of novel α ‐glucosidase inhibitors in okara fermented with Bacillus amyloliquefaciens YP2. Journal of the Science of Food and Agriculture, 106(1), 354-364. https://doi.org/10.1002/jsfa.70185
Vancouver
Ji N, Li HL, Ren F, Zhang Y, Zhao B, Chen C, et al. Purification and identification of novel α ‐glucosidase inhibitors in okara fermented with Bacillus amyloliquefaciens YP2. Journal of the Science of Food and Agriculture. 2026;106(1):354-364. doi:10.1002/jsfa.70185
BibTeX
@article{Ji2026,
author = {Ji, Nairu and Li, Hui-Lin and Ren, Fei and Zhang, Yingqi and Zhao, Bingyu and Chen, Chang and Zhu, Yunping},
title = {Purification and identification of novel α ‐glucosidase inhibitors in okara fermented with Bacillus amyloliquefaciens YP2},
journal = {Journal of the Science of Food and Agriculture},
year = {2026},
volume = {106},
number = {1},
pages = {354--364},
doi = {10.1002/jsfa.70185}
}
EUVIMED